# MAGEA1

## Overview
The MAGEA1 gene encodes the protein MAGE family member A1, which is part of the melanoma-associated antigen (MAGE) family. This family is characterized by its expression in germ cells and various tumors, making it a member of the cancer/testis antigen group. MAGEA1 is primarily expressed in male and female germ cells, playing a crucial role in early germ cell development and viability (Lee2017A). The protein is involved in forming complexes with E3 RING ubiquitin ligases, known as MAGE-RING ligases, which regulate ubiquitination processes critical for cellular functions such as protein degradation and DNA repair (Lee2017A). MAGEA1's interactions with other proteins, such as CTCF and DNMT3a, underscore its role in transcriptional regulation through epigenetic modifications (Zhao2018MAGEA1). Clinically, MAGEA1 is significant in oncology, particularly in melanoma and neuroblastoma, where its expression and mutations are associated with tumorigenesis and prognosis, respectively (Grau2008MAGEA1; Caballero2010Frequent).

## Function
The MAGEA1 gene encodes a protein that is part of the MAGE family, which is primarily expressed in germ cells, particularly in the testis. MAGEA1 plays a significant role in germ cell development, being expressed in spermatogonia and primary spermatocytes, but not in later stages of spermatogenesis such as spermatids or Sertoli cells. This expression pattern suggests its involvement in the early stages of spermatogenesis and in maintaining germ cell viability and development (Lee2017A). MAGEA1 is also expressed in migrating primordial germ cells in embryos, indicating its role in early germ cell development. In female germ cells, MAGEA1 is expressed in oogonia prenatally, suggesting a role in female germ cell development as well (Lee2017A).

Beyond germ cells, MAGEA1 and other MAGE-A proteins may be involved in neuronal development, as they are detected in the spinal cord, brain stem, and peripheral nerves during early CNS development (Lee2017A). MAGEA1 proteins form complexes with E3 RING ubiquitin ligases, creating MAGE-RING ligases (MRLs) that regulate ubiquitination, influencing various cellular processes such as protein degradation, DNA repair, and transcription factor activation (Lee2017A).

## Clinical Significance
The MAGEA1 gene is clinically significant due to its role in various cancers, particularly melanoma and neuroblastoma. In melanoma, MAGEA1 is part of the cancer/testis antigen family and is frequently mutated, with mutations found in approximately 3.7% to 6% of cases. These mutations, such as S33F and L129L, suggest a potential role in tumorigenesis, although their exact function remains unclear (Caballero2010Frequent). The gene's expression in melanoma is often associated with DNA hypomethylation, which leads to its activation and the production of tumor-specific antigens, making it a target for cancer immunotherapy (Cannuyer2013Epigenetic).

In neuroblastoma, MAGEA1 expression is linked to a favorable prognosis, particularly in localized tumors without N-Myc amplification. Its expression is associated with better event-free and overall survival rates, making it an independent prognostic factor (Grau2008MAGEA1). The gene's expression in neuroblastoma is regulated by epigenetic mechanisms, including DNA methylation and chromatin structure changes, with a significant correlation between its expression and hypomethylation (Grau2008MAGEA1). These findings highlight the potential of MAGEA1 as a biomarker and therapeutic target in cancer treatment.

## Interactions
MAGEA1 interacts with several proteins and plays a role in complex regulatory mechanisms. It forms a complex with CTCF and DNMT3a, which is crucial for the hypermethylation and repression of the BORIS promoter, leading to cell death in breast cancer cell lines. This interaction is essential for recruiting DNMT3a to the BORIS promoter, highlighting the role of MAGEA1 in transcriptional regulation through epigenetic modifications (Zhao2018MAGEA1).

MAGEA1 also interacts with CTCF, a transcription factor necessary for its binding to the BORIS promoter. This interaction is supported by co-immunoprecipitation and GST-pulldown assays, indicating a physical association between MAGEA1 and CTCF in the nucleus, which may influence transcription factor activities (Zhao2018MAGEA1).

In the context of bladder cancer, MAGEA1 is part of the MAGEA protein family, which shares interactions with other MAGE proteins, such as MAGEA2B, MAGEB10, and MAGEB2. These interactions are significant as they influence the tumor microenvironment and promote cell proliferation by affecting various signaling pathways (Verma2024Melanoma).


## References


[1. (Zhao2018MAGEA1) Jizhong Zhao, Yueqing Wang, Qianjin Liang, Yan Xu, and Jianli Sang. Magea1 inhibits the expression of boris via increased promoter methylation. Journal of Cell Science, January 2018. URL: http://dx.doi.org/10.1242/jcs.218628, doi:10.1242/jcs.218628. This article has 2 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.218628)

[2. (Caballero2010Frequent) Otavia L. Caballero, Qi Zhao, Donata Rimoldi, Brian J. Stevenson, Suzanne Svobodová, Sylvie Devalle, Ute F. Röhrig, Anna Pagotto, Olivier Michielin, Daniel Speiser, Jedd D. Wolchok, Cailian Liu, Tanja Pejovic, Kunle Odunsi, Francis Brasseur, Benoit J. Van den Eynde, Lloyd J. Old, Xin Lu, Jonathan Cebon, Robert L. Strausberg, and Andrew J. Simpson. Frequent mage mutations in human melanoma. PLoS ONE, 5(9):e12773, September 2010. URL: http://dx.doi.org/10.1371/journal.pone.0012773, doi:10.1371/journal.pone.0012773. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0012773)

[3. (Cannuyer2013Epigenetic) Julie Cannuyer, Axelle Loriot, Grégory K. Parvizi, and Charles De Smet. Epigenetic hierarchy within the magea1 cancer-germline gene: promoter dna methylation dictates local histone modifications. PLoS ONE, 8(3):e58743, March 2013. URL: http://dx.doi.org/10.1371/journal.pone.0058743, doi:10.1371/journal.pone.0058743. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0058743)

[4. (Grau2008MAGEA1) Elena Grau, Silvestre Oltra, Francisco Martínez, Carmen Orellana, Adela Cañete, Jose María Fernández, Miguel Hernández-Martí, and Victoria Castel. Mage-a1 expression is associated with good prognosis in neuroblastoma tumors. Journal of Cancer Research and Clinical Oncology, 135(4):523–531, September 2008. URL: http://dx.doi.org/10.1007/s00432-008-0484-1, doi:10.1007/s00432-008-0484-1. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00432-008-0484-1)

[5. (Lee2017A) Anna K. Lee and Patrick Ryan Potts. A comprehensive guide to the mage family of ubiquitin ligases. Journal of Molecular Biology, 429(8):1114–1142, April 2017. URL: http://dx.doi.org/10.1016/j.jmb.2017.03.005, doi:10.1016/j.jmb.2017.03.005. This article has 101 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2017.03.005)

[6. (Verma2024Melanoma) Shiv Verma, Diya Swain, Prem Prakash Kushwaha, Smit Brahmbhatt, Karishma Gupta, Debasish Sundi, and Sanjay Gupta. Melanoma antigen family a (mage a) as promising biomarkers and therapeutic targets in bladder cancer. Cancers, 16(2):246, January 2024. URL: http://dx.doi.org/10.3390/cancers16020246, doi:10.3390/cancers16020246. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers16020246)